Calculating And Understanding Particulate Contamination Risk - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Calculating And Understanding Particulate Contamination Risk
The author presents a method to calculate the relationship between supply air volume flow and airborne particle concentrations. These methods and approaches facilitate the overall understanding of airborne contaminants and provide valuable information when designing facilities and processes for sterile manufacturing.


Pharmaceutical Technology Europe
Volume 23, Issue 3

As a practical example, the model can be used to calculate the contamination rate if the exposure time for ampoules in a blowfillseal filling machine is increased. Many types of blowfillseal filling machines generate a high amount of particles during plastic extrusion. Often, these particles are removed through local exhaust devices inside the machine region. To improve the local exhaust devices and thereby remove more airborne particles, the cycle time was increased, allowing the mould to stay at the extrusion position for a longer time. In this case, the concentration of airborne particles in the filling machine was reduced. However, the increased cycle time and exposure time must also be taken into account when evaluating the overall risk situation. The calculated contamination rate was increased 20% due to increased exposure time (20% longer). The concentration of airborne particles was decreased by 25%. In the end, considering both the increased exposure time and the reduced concentration of airborne particles, the contamination risk decreased by 5%.

As another example, comparisons can be made between different filling techniques. If vials in filling process A have the same exposed area, airborne concentration and settling velocity as ampoules in process B, but twice the exposure time, the calculated contamination rate is doubled for process A. The guidelines1,2 do not make any exceptions between these two techniques, but in theory, the airborne concentration at process B could be twice as high as for process A and still have equal contamination risk.

Conclusion

The calculation models presented in this article can be helpful in calculating risk factors and increasing the understanding of contamination caused by airborne particles. The method described shows that it is possible to calculate the risk factor or the rate of contaminations to a certain area. The theoretical risk to contaminate, for example, a container or ampoule, depends on the exposed neck area, airborne particle concentration and exposure time.

Mattias Haag is Validation Manager at Energo, Stockholm (Sweden).
Tel. +46 10 470 60 00

References

1. EU GMP European Commission, The Rules Governing Medicinal Products in the European Union, Vol. 4, EU Guidelines to Good Manufacturing Practice, Annex 1, Manufacture of Sterile Medicinal Products, 1997 (revised 2008).

2. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice. Rockville, MD, 2004.

3. B. Ljungqvist and B. Reinmüller, Clean Room Design: Minimizing Contamination Through Proper Design (CRC Press LLC, Boca Raton, Florida, USA, 1997).

4. B. Ljungqvist, Some Observations on the Interaction Between Air Movements and the Dispersion of Pollution: Document D8:1979, Swedish Council for Building Research, Stockholm, Sweden (1979).

5. W. Whyte, Journal of Parenteral Science & Technology, 40(5) 188-197 (1986).

6. S. Sundström, B. Ljungqvist and B. Reinmüller, European Journal of parenteral & Pharmaceutical Science, 15(3) 87–92 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here